SCHEMBL2680971

SCHEMBL2680971

O=C(CCl)Nc1ccc(O)c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 2/20 0.60
IDO1 P14902 10/20 0.54
KAT2B Q92831 1/20 0.51
KAT8 Q9H7Z6 1/20 0.51
ALDH1A1 P00352 4/20 0.51
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
NPC1 O15118 1/20 0.49
MITF O75030 1/20 0.49
RAB9A P51151 1/20 0.49
CDC25B P30305 1/20 0.47
MEN1 O00255 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8028208 0.90 ALDH1A1 (0.59) EP300ALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL12599077 0.83 EP300 (0.60) EP300IDO1KAT2BKAT8CDC25B
SCHEMBL4866643 0.83 ALDH1A1 (0.51) EP300ALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL9729961 0.83 EP300 (0.60) EP300IDO1KAT2BKAT8CDC25B
SCHEMBL4604147 0.78 ALDH1A1 (0.57) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL2479073 0.78 IDO1 (0.60) EP300IDO1KAT2BKAT8CDC25B
SCHEMBL11418892 0.78 IDO1 (0.65) EP300IDO1KAT2BKAT8CDC25B
SCHEMBL29728210 0.77 MAPT (0.68) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL4867099 0.77 MAPT (0.68) ALDH1A1HTTSMN1; SMN2LMNANPC1
SCHEMBL4011016 0.77 ALDH1A1 (0.65) ALDH1A1HTTSMN1; SMN2LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932300-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2018-04-03 US disclosed
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-11-03 US disclosed
US-9421211-B2 N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-08-23 US disclosed
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2012-05-10 US disclosed
EP-0603954-B1 Immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer JOHNSON & JOHNSON CLIN DIAG (US) 2000-03-08 EP disclosed
EP-0603953-B1 Use of 4' of 5'-hydroxy and 4'- or 5'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods JOHNSON & JOHNSON CLIN DIAG (US) 1999-02-17 EP disclosed
US-5736335-A Dry elements, test devices, test kits and methods for chemiluminescent detection of analytes using peroxidase-labeled reagents EASTMAN KODAK COMPANY (US) 1998-04-07 US disclosed
US-5641635-A Dry elements, test devices, test kits and methods for chemiluminescent detection of analytes using peroxidase-labeled reagents EASTMAN KODAK COMPANY (US) 1997-06-24 US disclosed
US-5372931-A Use of 4'-hydroxy- and 4'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods EASTMAN KODAK COMPANY (US) 1994-12-13 US disclosed
US-5372932-A Peroxidase-labeled immunoreactant; stabiliztion with a 4-hydroxy or 4-alkoxyarylacetamide EASTMAN KODAK COMPANY (US) 1994-12-13 US disclosed
EP-0603953-A1 Use of 4' of 5'-hydroxy and 4'- or 5'-alkoxy-substituted electron transfer agents in compositions, elements, test kits and analytical methods Johnson & Johnson Clinical Diagnostics, Inc. (US) 1994-06-29 EP disclosed
EP-0603954-A2 Analytical element and immunoassay using a 4-hydroxy or 4-alkoxyarylacetamide as stabilizer Johnson & Johnson Clinical Diagnostics, Inc. (US) 1994-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318857-A1 N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation NSUN2, EIF2AK2, RNGTT EP300 1188/4885IDO1 3237/4885KAT2B 1857/4885
US-20120115915-A1 N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION NSUN2, EIF2AK2, RNGTT EP300 1188/4885IDO1 3237/4885KAT2B 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.